EZH2 and breast cancer: Allosteric and active site-directed mTOR inhibitors also reduced EZH2 and SUZ12 protein expression in human ERBB2+ breast cancer cell lines (SkBr3 and MDA-MB-361), but not a triple-negative breast cancer (TNBC) cell line (MDA-MB-231), in a manner commensurate with their ability to decrease EIF4EBP1 phosphorylation (Supplementary Fig. 5g).